Genetic Defects as Tumor Markers

Molecular Biology

Volumn 37, Issue 2, 2003, Pages 159-169

  Lichtenstein, A V ^a   Potapova, G I ^a  

^a N N BLOKHIN RUSSIAN CANCER RESEARCH CENTER   (Russian Federation)

Author keywords

Aging; Apoptosis; Cancer; Carcinogenesis; DNA markers; Gene diagnosis; Mutations; Oncogenes; Suppressor genes; Tumor markers

Indexed keywords

ALPHA FETOPROTEIN; CELL NUCLEUS DNA; DNA FRAGMENT; DNA MARKER; MICROSATELLITE DNA; MITOCHONDRIAL DNA; PROTEIN; PROTEIN BCL 2; TELOMERASE; TUMOR MARKER; UVOMORULIN; VASCULOTROPIN;

ALLELE; APOPTOSIS; BLOOD; BODY FLUID; CANCER RECURRENCE; CANCER RISK; CANCER SCREENING; CARCINOGENESIS; CELL DIVISION; CELL FUNCTION; CIRCULATION; DIAGNOSTIC TEST; DNA DETERMINATION; DNA REPAIR; EARLY DIAGNOSIS; EPIGENETICS; GENE FUNCTION; GENE LOCUS; GENETIC DAMAGE; GENETIC DISORDER; GENOME; HETEROZYGOSITY; HIGH RISK POPULATION; HUMAN; LIGASE CHAIN REACTION; MALIGNANT NEOPLASTIC DISEASE; MATRIX ASSISTED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY; METASTASIS; METHYLATION; MITOCHONDRIAL DNA DISORDER; MUTANT; MUTATION; ONCOGENE H RAS; PATHOGENESIS; PHENOTYPE; POLYMERASE CHAIN REACTION; REVIEW; RNA SYNTHESIS; SYMPTOMATOLOGY; TECHNIQUE; THEORY; TREATMENT OUTCOME; TUMOR CELL; TUMOR DIAGNOSIS; TUMOR GROWTH; URINE;

EID: 0037272896     PISSN: 00268933     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1023329201643     Document Type: Review

References (95)

1. Marks P., Rifkind R.A., Richon V.M., Breslow R., Miller T., Kelly W.K. 2001. Histone deacetylases and cancer: causes and therapies. Nature Rev. Cancer. 1, 194-202.
2. Weinberg R.A. 2002. Cancer biology and therapy: the road ahead. Cancer Biol. Ther. 1, 3.
3. Bykov V.J., Issaeva N., Shilov A., Hultcrantz M., Pugacheva E., Chumakov P., Bergman J., Wiman K.G., Selivanova G. 2002. Restoration of the tumor suppressor function to mutant P53 by a low- molecular-weight compound. Nature Med. 8, 282-288.
4. Hahn W.C., Weinberg R.A. 2002. Modelling the molecular circuitry of cancer. Nature Rev. Cancer. 2, 331-341.
5. Hanahan D., Weinberg R.A. 2000. The hallmarks of cancer. Cell. 100, 57-70.
6. Sidransky D. 2002. Emerging molecular markers of cancer. Nature Rev. Cancer. 2, 210-219.
7. Loeb L.A. 2001. A mutator phenotype in cancer. Cancer Res. 61, 3230-3239.
8. Herman J.G. 1999. Hypermethylation of tumor suppressor genes in cancer. Semin. Cancer Biol. 9, 359-367.
9. Bird A. 2002. DNA Methylation patterns and epigenetic memory. Genes Dev. 16, 6-21.
10. Esteller M., Gaidano G., Goodman S.N., Zagonel V., Capello D., Botto B., Rossi D., Gloghini A., Vitolo U., Carbone A., Baylin S.B., Herman J.G. 2002. Hypermethylation of the DNA repair gene O(6)-methylguanine DNA methyltransferase and survival of patients with diffuse large B-cell lymphoma. J. Natl. Cancer Inst. 94, 26-32.
11. Jones P.A., Baylin S.B. 2002. The fundamental role of epigenetic events in cancer. Nature Rev. Genet. 3, 415-428.
12. Lichtenstein A.V. and Kisseljova N.P. 2001. DNA methylation and carcinogenesis. Biokhimiya. 66, 293-317.
13. Holliday R. 1991. Mutations and epimutations in mammalian cells. Mutat. Res. 250, 351-363.
14. Baylin S.B., Herman J.G., Graff J.R., Vertino P.M., Issa J.P. 1998. Alterations in DNA methylation: a fundamental aspect of neoplasia. Adv. Cancer Res. 72, 141-196.
15. Kisseljova N.P. and Kisseljov F.L. 2000. Epigenetic changes and carcinogenesis. Kantserogenez (Carcinogenesis). Ed Zaridze D.G. Moscow: Nauchnyi Mir. 93-105.
16. Zborovskaya I.B. 2000. Molecular biological analysis of oncogenes and tumor suppressor genes in clinical practice. Kantserogenez (Carcinogenesis). Ed Zaridze D.G. Moscow: Nauchnyi Mir. 361-379.
17. Costello J.F., Fruhwald M.C., Smiraglia D.J., Rush L.J., Robertson G.P., Gao X., Wright F.A., Feramisco J.D., Peltomaki P., Lang J.C., Schuller D.E., Yu L., Bloomfield C.D., Caligiuri M.A., Yates A., Nishikawa R., Su H.H., Petrelli N.J., Zhang X., O'Dorisio M.S., Held W.A., Cavenee W.K., Plass C. 2000. Aberrant CpG-island methylation has non-random and tumour-type-specific patterns. Nature Genet. 24, 132-138.
18. Esteller M., Corn P.G., Baylin S.B., Herman J.G.A. 2001. Gene hypermethylation profile of human cancer. Cancer Res. 61, 3225-3229.
19. Nomoto S., Yamashita K., Koshikawa K., Nakao A., Sidransky D. 2002. Mitochondrial D-loop mutations as clonal markers in multicentric hepatocellular carcinoma and plasma. Clin. Cancer Res. 8, 481-487.
20. Johnson P.J., Lo Y.M. 2002. Plasma nucleic acids in the diagnosis and management of malignant disease. Clin. Chem. 48, 1186-1193.
21. Kopreski M.S., Benko F.A., Kwak L.W., Gocke C.D. 1999. Detection of tumor messenger RNA in the serum of patients with malignant melanoma. Clin. Cancer Res. 5, 1961-1965.
22. Rappl G., Hasselmann D.O., Rossler M., Ugurel S., Tilgen W., Reinhold U. 2001. Detection of tumor-associated circulating mRNA in patients with disseminated malignant melanoma. Ann. N. Y. Acad. Sci. 945, 189-191.
23. Chen X.Q., Bonnefoi H., Pelte M.F., Lyautey J., Lederrey C., Movarekhi S., Schaeffer P., Mulcahy H.E., Meyer P., Stroun M., Anker P. 2000. Telomerase RNA as a detection marker in the serum of breast cancer patients. Clin. Cancer Res. 6, 3823-3826.
24. Dasi F., Lledo S., Garcia-Granero E., Ripoll R., Marugan M., Tormo M., Garcia-Conde J., Alino S.F. 2001. Real-time quantification in plasma of human telomerase reverse transcriptase (HTERT) mRNA: a simple blood test to monitor disease in cancer patients. Lab. Invest. 81, 767-769.
25. Abelev G.I. 1971. Alpha-fetoprotein in ontogenesis and its association with malignant tumors. Adv. Cancer Res. 14, 295-358.
26. Abelev G.I., Eraiser T.L. 1999. Cellular aspects of alpha-fetoprotein reexpression in tumors. Semin. Cancer Biol. 9, 95-107.
27. Abelev G.I. 2000. Immunology of human tumors. Kantserogenez (Carcinogenesis). Ed Zaridze D.G. Moscow: Nauchnyi Mir. 333-341.
28. Eisenberger C.F., Schoenberg M., Enger C., Hortopan S., Shah S., Chow N.H., Marshall F.F., Sidransky D. 1999. Diagnosis of renal cancer by molecular urinalysis. J. Natl. Cancer Inst. 91, 2028-2032.
29. Goessl C., Muller M., Heicappell R., Krause H., Miller K. 2001. DNA-based detection of prostate cancer in blood, urine, ejaculates. Ann. N. Y. Acad. Sci. 945, 51-58.
30. Holdenrieder S., Stieber P., Bodenmuller H., Fertig G., Furst H., Schmeller N., Untch M., Seidel D. 2001. Nucleosomes in serum as a marker for cell death. Clin. Chem. Lab. Med. 39, 596-605.
31. Holdenrieder S., Stieber P., Bodenmuller H., Busch M., Fertig G., Furst H., Schalhorn A., Schmeller N., Untch M., Seidel D. 2001. Nucleosomes in serum of patients with benign and malignant diseases. Int. J. Cancer. 95, 114-120.
32. Fournie G.J., Martres F., Pourrat J.P., Alary C., Rumeau M. 1993. Plasma DNA as cell death marker in elderly patients. Gerontology. 39, 215-221.
33. Fournie G.J., Courtin J.P., Laval F., Chale J.J., Pourrat J.P., Pujazon M.C., Lauque D., Carles P. 1995. Plasma DNA as a marker of cancerous cell death. Investigations in patients suffering from lung cancer and in nude mice bearing human tumours. Cancer Lett. 91, 221-227.
34. Tsumita T., Iwanaga M. 1963. Fate of injected deoxyribonucleic acid in mice. Nature. 198, 70-71.
35. Botezatu I., Serdyuk O., Potapova G., Shelepov V., Alechina R., Molyaka Y., Ananev V., Bazin I., Garin A., Narimanov M., Knysh V., Melkonyan H., Umansky S., Lichtenstein A. 2000. Genetic analysis of DNA excreted in urine: a new approach for detecting specific genomic DNA sequences from cells dying in an organism. Clin. Chem. 46, 1078-1084.
36. Shapot V.S. 1968. Nukleasy (Nucleases). Moscow: Meditsina.
37. Chen X.Q., Stroun M., Magnenat J.-L., Nicod L.P., Kurt A.-M., Lyautey J., Lederrey C., Anker P. 1996. Microsatellite alterations in plasma DNA of small cell lung cancer patients. Nature Med. 2, 1033-1035.
38. Nawroz H., Koch W., Anker P., Stroun M., Sidransky D. 1996. Microsatellite alterations in serum DNA of head and neck cancer patients. Nature Med. 2, 1035-1037.
39. Kopreski M.S., Benko F.A., Kwee C., Leitzel K.E., Eskander E., Lipton A., Gocke C. 1997. Detection of mutant K-RAS DNA in plasma or serum of patients with colorectal cancer. Br. J. Cancer. 76, 1293-1299.
40. Mulcahy H.E., Lyautey J., Lederrey C., Chen X., Anker P., Alstead E.M., Ballinger A., Farthing M.J., Stroun M. 1998. A prospective study of K-RAS mutations in the plasma of pancreatic cancer patients. Clin. Cancer Res. 4, 271-275.
41. Anker P., Mulcahy H., Chen X.Q., Stroun M. 1999. Detection of circulating tumour DNA in the blood (Plasma/Serum) of cancer patients. Cancer Metastasis Rev. 18, 65-73.
42. Gocke C.D., Benko F.A., Kopreski M.S., McGarrity T.J. 2000. P53 and APC mutations are detectable in the plasma and serum of patients with colorectal cancer (CRC) or adenomas. Ann. N. Y. Acad. Sci. 906, 44-50.
43. Kopreski M.S., Benko F.A., Borys D.J., Khan A., McGarrity T.J., Gocke C.D. 2000. Somatic mutation screening: identification of individuals harboring K-Ras mutations with the use of plasma DNA. J. Natl. Cancer Inst. 92, 918-923.
44. Jeronimo C., Nomoto S., Caballero O.L., Usadel H., Henrique R., Varzim G., Oliveira J., Lopes C., Fliss M.S., Sidransky D. 2001. Mitochondrial mutations in early stage prostate cancer and bodily fluids. Oncogene. 20, 5195-5198.
45. Lichtenstein A.V., Melkonyan H.S., Tomei L.D., Umansky S.R. 2001. Circulating nucleic acids and apoptosis. Ann. N. Y. Acad. Sci. 945, 239-249.
46. Jahr S., Hentze H., Englisch S., Hardt D., Fackelmayer F.O., Hesch R.D., Knippers R. 2001. DNA fragments in the blood plasma of cancer patients: quantitations and evidence for their origin from apoptotic and necrotic cells. Cancer Res. 61, 1659-1665.
47. Umansky S.R. 1996. Apoptosis: molecular and cellular mechanisms. Mol. Biol. 30, 487-502.
48. Holdenrieder S., Stieber P., Bodenmuller H., Busch M., Von Pawel J., Schalhorn A., Nagel D., Seidel D. 2001. Circulating nucleosomes in serum. Ann. N. Y. Acad. Sci. 945, 93-102.
49. Giacona M.B., Ruben G.C., Iczkowski K.A., Roos T.B., Porter D.M., Sorenson G.D. 1998. Cell-free DNA in human blood plasma: length measurements in patients with pancreatic cancer and healthy controls. Pancreas. 17, 89-97.
50. Halicka H.D., Bedner E., Darzynkiewicz Z. 2000. Segregation of RNA and separate packaging of DNA and RNA in apoptotic bodies during apoptosis. Exp. Cell Res. 260, 248-256.
51. van Wijk I.J., de Hoon A.C., Jurhawan R., Tjoa M.L., Griffioen S., Mulders M.A., van Vugt J.M., Oudejans C.B. 2000. Detection of apoptotic fetal cells in plasma of pregnant women. Clin. Chem. 46, 729-731.
52. Hasselmann D.O., Rappl G., Tilgen W., Reinhold U. 2001. Extracellular tyrosinase mRNA within apoptotic bodies is protected from degradation in human serum. Clin. Chem. 47, 1488-1489.
53. Chiu R.W., Poon L.L., Lau T.K., Leung T.N., Wong E.M., Lo Y.M. 2001. Effects of blood-processing protocols on fetal and total DNA quantification in maternal plasma. Clin. Chem. 47, 1607-1613.
54. Ng E.K., Tsui N.B., Lam N.Y., Chiu R.W., Yu S.C., Wong S.C., Lo E.S., Rainer T.H., Johnson P.J., Lo Y.M. 2002. Presence of filterable and nonfilterable mRNA in the plasma of cancer patients and healthy individuals. Clin. Chem. 48, 1212-1217.
55. Holcik M. 2001. Deadly revenge: uptake of oncogenes from apoptotic bodies. Trends Genet. 17, 491.
56. Holmgren L., Szeles A., Rajnavolgyi E., Folkman J., Klein G., Ernberg I., Falk K.I. 1999. Horizontal transfer of DNA by the uptake of apoptotic bodies. Blood. 93, 3956-3963.
57. Bickerstaff M.C., Botto M., Hutchinson W.L., Herbert J., Tennent G.A., Bybee A., Mitchell D.A., Cook H.T., Butler P.J., Walport M.J., Pepys M.B. 1999. Serum amyloid P component controls chromatin degradation and prevents antinuclear autoimmunity. Nature Med. 5, 694-697.
58. Butler P.J., Tennent G.A., Pepys M.B. 1990. Pentraxin-Chromatin Interactions: Serum amyloid P component specifically displaces H1-type histones and solubilizes native long chromatin. J. Exp. Med. 172, 13-18.
59. Edwards P.A.W., Sherley J.L., Bernards R., Weinberg R.A. 2002. Metastasis: the role of chance in malignancy. Nature. 419, 559-560.
60. Lakhani S.R., Ashworth A. 2001. Microarray and histopathological analysis of tumours: the future and the past? Nature Rev. Cancer. 1, 151-157.
61. Lakhani S.R. 2001. Molecular genetics of solid tumours: translating research into clinical practice. What we could do now: Breast Cancer. Mol. Pathol. 54, 281-284.
62. Steiner G., Schoenberg M.P., Linn J.F., Mao L., Sidransky D. 1997. Detection of bladder cancer recurrence by microsatellite analysis of urine. Nature Med. 3, 621-624.
63. Sidransky D., Tokino T., Hamilton S.R., Kinzler K.W., Levin B., Frost P., Vogelstein B. 1992. Identification of Ras oncogene mutations in the stool of patients with curable colorectal tumors. Science. 256, 102-105.
64. Tada M., Omata M., Kawai S., Saisho H., Ohto M., Saiki R.K., Sninsky J.J. 1993. Detection of Ras gene mutations in pancreatic juice and peripheral blood of patients with pancreatic adenocarcinoma. Cancer Res. 53, 2472-2474.
65. Boyle J.O., Mao L., Brennan J.A., Koch W.M., Eisele D.W., Saunders J.R., Sidransky D. 1994. Gene mutations in saliva as molecular markers for head and neck squamous cell carcinomas. Am. J. Surg. 168, 429-432.
66. Koch W.M., Boyle J.O., Mao L., Hakim J., Hruban R.H., Sidransky D. 1994. P53 Gene mutations as markers of tumor spread in synchronous oral cancers. Arch. Otolaryngol. Head Neck Surg. 120, 943-947.
67. Ahrendt S.A., Chow J.T., Xu L.H., Yang S.C., Eisenberger C.F., Esteller M., Herman J.G., Wu L., Decker P.A., Jen J., Sidransky D. 1999. Molecular detection of tumor cells in bronchoalveolar lavage fluid from patients with early stage lung cancer. J. Natl. Cancer Inst. 91, 332-339.
68. Ronai Z., Yakubovskaya M.S., Zhang E., Belitsky G.A. 1996. K-RAS mutation in sputum of patients with or without lung cancer. J. Cell Biochem. Suppl. 25, 172-176.
69. Yakubovskaya M.S., Spiegelman V., Luo F.C., Malaev S., Salnev A., Zborovskaya I., Gasparyan A., Polotsky B., Machaladze Z., Trachtenberg A.C. 1995. High frequency of K-RAS mutations in normal appearing lung tissues and sputum of patients with lung cancer. Int. J. Cancer. 63, 810-814.
70. Gonzalez R., Silva J.M., Sanchez A., Dominguez G., Garcia J.M., Chen X.Q., Stroun M., Provencio M., Espana P., Anker P., Bonilla F. 2000. Microsatellite alterations and TP53 mutations in plasma DNA of small-cell lung cancer patients: follow-up study and prognostic significance. Ann. Oncol. 11, 1097-1104.
71. Mulcahy H.E., Lyautey J., Lederrey C., Chen X.Q., Lefort F., Vasioukhin V., Anker P., Alstead E.M., Farthing M.J., Stroun M. 2000. Plasma DNA K-RAS mutations in patients with gastrointestinal malignancies. Ann. N. Y. Acad. Sci. 906, 25-28.
72. van Rhijn B.W., Lurkin I., Kirkels W.J., van der Kwast T.H., Zwarthoff E.C. 2001. Microsatellite analysis - DNA test in urine competes with cystoscopy in follow-up of superficial bladder carcinoma: a phase II Trial. Cancer. 92, 768-775.
73. Burchill S.A., Selby P.J. 2000. Molecular detection of low-level disease in patients with cancer. J. Pathol. 190, 6-14.
74. Zaridze D.G. 2000. Epidemiology and etiology of malignant neoplasms. Kantserogenez (Carcinogenesis). Ed Zaridze D.G. Moscow: Nauchnyi Mir. 21-56.
75. DePinho R.A. 2000. The age of cancer. Nature. 408, 248-254.
76. Shabad L.M. 1967. Predrak v experimental'no-morfologicheskom aspekte (The Experimental Morphological Aspect of Precancer). Moscow: Meditsina.
77. Takayama T., Katsuki S., Takahashi Y., Ohi M., Nojiri S., Sakamaki S., Kato J., Kogawa K., Miyake H., Niitsu Y. 1998. Aberrant crypt foci of the colon as precursors of adenoma and cancer. N. Engl. J. Med. 339, 1277-1284.
78. Finkel T., Holbrook N.J. 2000. Oxidants, oxidative stress and the biology of ageing. Nature. 408, 239-247.
79. Johnson F.B., Sinclair D.A., Guarente L. 1999. Molecular biology of aging. Cell. 96, 291-302.
80. Toyota M., Issa J.-P. 1999. CpG island methylator phenotypes in aging and cancer. Semin. Cancer Biol. 9, 349-357.
81. Reya T., Morrison S.J., Clarke M.F., Weissman I.L. 2001. Stem cells, cancer, and cancer stem cells. Nature. 414, 105-111.
82. Mathon N.F., Lloyd A.C. 2001. Cell senescence and cancer. Nature Rev. Cancer. 1, 203-213.
83. Minamoto T., Esumi H., Ochiai A., Belitsky G., Mai M., Sugimura T., Ronai Z. 1997. Combined analysis of microsatellite instability and K-RAS mutation increases detection incidence of normal samples from colorectal cancer patients. Clin. Cancer Res. 3, 1413-1417.
84. Ronai Z., Minamoto T., Butler R., Tobi M., Luo F.Q., Zang E., Esumi H., Sugimura T. 1995. Sampling method as a key factor in identifying K-RAS oncogene mutations in preneoplastic colorectal lesions. Cancer Detect. Prev. 19, 512-517.
85. Lizardi P.M., Huang X., Zhu Z., Bray-Ward P., Thomas D.C., Ward D.C. 1998. Mutation detection and single-molecule counting using isothermal rolling-circle amplification. Nature Genetics. 19, 225-232.
86. Sun X., Hung K., Wu L., Sidransky B., Guo B. 2002. Detection of tumor mutations in the presence of excess amounts of normal DNA. Nature Biotechnol. 20, 186-189.
87. Kahn S.M., Jiang W., Culbertson T.A., Weinstein I.B., Williams G.M., Tomita N., Ronai Z. 1991. Rapid and sensitive nonradioactive detection of mutant K-Ras genes via 'Enriched' PCR amplification. Oncogene. 6, 1079-1083.
88. Haliassos A., Chomel J.C., Grandjouan S., Kruh J., Kaplan J.C., Kitzis A. 1989. Detection of minority point mutations by modified PCR technique: a new approach for a sensitive diagnosis of tumor-progression markers. Nucleic Acids Res. 17, 8093-8099.
89. Takeda S., Ichii S., Nakamura Y. 1993. Detection of K-RAS mutation in sputum by mutant-allele-specific amplification (MASA). Hum. Mutat. 2, 112-117.
90. Lichtenstein A.V., Serdjuk O.I., Sukhova T.I., Melkonyan H.S., Umansky S.R. 2001. Selective 'Stencil'-aided pre-PCR cleavage of wild-type sequences as a novel approach to detection of mutant K-RAS. Nucleic Acids Res. 29, E90.
91. Behn M., Schuermann M. 1998. Sensitive detection of P53 gene mutations by a 'mutant enriched' PCR-SSCP technique. Nucleic Acids Res. 26, 1356-1358.
92. Orum H., Nielsen P.E., Egholm M., Berg R.H., Buchardt O., Stanley C. 1993. Single base pair mutation analysis by PNA directed PCR clamping. Nucleic Acids Res. 21, 5332-5336.
93. Ward R., Hawkins N., O'Grady R., Sheehan C., O'Connor T., Impey H., Roberts N., Fuery C., Todd A. 1998. Restriction endonuclease-mediated selective polymerase chain reaction: a novel assay for the detection of K-RAS mutations in clinical samples. Am. J. Pathol. 153, 373-379.
94. Barany F. 1991. Genetic disease detection and DNA amplification using cloned thermostable ligase. Proc. Natl. Acad. Sci. USA. 88, 189-193.
95. Zimmermann K., Mannhalter J.W. 1996. Technical aspects of quantitative competitive PCR. Biotechniques. 21, 268-269.